评论 9
过滤器:
评分
语言
种类:
最近的
E
6 几个月前

I absolutely 😊 love the services provided by Lycer...

I absolutely 😊 love the services provided by Lycera! Their website is so easy to use and navigate. The customer support team👌 is always helpful and quick to respond to any queries. I am extremely satisfied with their services!

M
6 几个月前

I recently had a positive experience with Lycera. ...

I recently had a positive experience with Lycera. The company's website is user-friendly, and their customer service is excellent. They provided me with the best solution for my requirements. I highly recommend Lycera for their services.

S
10 几个月前

I've been a customer of Lycera for a while now, an...

I've been a customer of Lycera for a while now, and I must say they have never disappointed. Their website is easy to navigate, and their customer service is excellent. I am extremely satisfied with their services.

J
10 几个月前

I recently had the opportunity to work with Lycera...

I recently had the opportunity to work with Lycera and I must say it was an average experience. The company's website is user-friendly and easy to navigate. However, I found their customer service to be lacking. Overall, I would rate my experience with Lycera as average.

R
1年以前

Working with Lycera has been a wonderful experienc...

Working with Lycera has been a wonderful experience. The company's website is user-friendly, and their customer service is top-notch. They were able to meet all of my requirements and deliver outstanding results. I highly recommend Lycera!

A
1年以前

Lycera is absolutely amazing! 😊 Their services are...

Lycera is absolutely amazing! 😊 Their services are top-notch, and their customer support team is always there to assist you. I am highly impressed with their professionalism and expertise. Keep up the great work!

关于Lycera

Lycera:通过创新药物开发革新制药行业

Lycera 是一家领先的制药公司,致力于开发创新药物,为最需要的患者提供原创解决方案。多年来,该公司一直处于药物开发的前沿,并在制药行业的变革中取得了重大进展。

在 Lycera,我们相信每位患者都应该获得针对其医疗状况的安全有效的治疗。这就是为什么我们致力于开发能够解决未满足的医疗需求并改善患者预后的药物。我们的团队由经验丰富的科学家、研究人员和临床医生组成,他们孜孜不倦地开发能够真正改变人们生活的新疗法。

我们的方法

在 Lycera,我们采用独特的药物开发方法。我们专注于确定以前未探索过的新靶点和途径,这使我们能够开发具有新作用机制的药物。这种方法使我们在多个治疗领域发现了几种有前途的候选药物。

我们还在药物发现过程中利用高通量筛选、计算建模和人工智能 (AI) 算法等尖端技术。这些工具使我们能够比传统方法更快、更有效地识别潜在的候选药物。

我们的管道

Lycera 在免疫学、肿瘤学、神经学和代谢紊乱等不同治疗领域拥有广泛的候选药物管道。我们的主要候选药物 LYC-30937 是一流的口服肠道限制性 RORγt 反向激动剂,目前正在针对炎症性肠病 (IBD) 的临床试验中进行评估。

我们在临床前开发中还有其他几个有希望的候选药物,例如用于实体瘤的 LYC-55716 和用于自身免疫性疾病的 LYC-24076。这些候选药物在临床前研究中显示出显着疗效,并为患有这些疾病的患者带来了巨大希望。

伙伴关系

Lycera 与全球领先的学术机构、生物技术公司和制药公司合作,进一步推进我们的研究工作。我们认为,合作伙伴关系对于加速制药行业的创新至关重要。

2018 年,Lycera 与 Celgene Corporation(现为 Bristol Myers Squibb)签订了一项价值高达 1.05 亿美元的独家全球许可协议,外加根据该合作协议开发的每件产品的特许权使用费,重点是针对 T 辅助 17 细胞 (Th17) 的小分子,这些细胞发挥着关键作用在牛皮癣或红斑狼疮等自身免疫性疾病中。

结论

总之,Lycera 致力于使用尖端技术开发创新药物,同时与全球合作伙伴合作,通过解决未满足的医疗需求来改善患者的治疗效果。LYC-30937 在临床试验中取得进展时前景广阔,还有许多其他令人兴奋的发展发生在莱塞拉,这无疑将改变我们未来治疗各种疾病的方式。我们期待继续我们的使命,即通过创新药物开发来革新制药行业,并为全世界患者的生活带来积极影响!

已翻译